A new procedure reported in the current issue of Nature Biotechnology has been shown to be a safe and effective method for introducing stem cells into the retina. Implantation of a specially engineered patch of retinal pigment epithelium (RPE) cells derived from stem cells has restored some vision in two people with sight loss from [Read More]
News
Accessible Prescription Labels Offer Convenience and Safety
People who cannot read their prescription labels often make medication errors, sometimes leading to hospitalization or worse. To address this serious issue, several pharmacies now provide accessible prescription labels. Provided by En-Vision America, “Scriptability” labels provide a safe and convenient way to access prescription information for individuals who cannot read standard print. The labels are [Read More]
Aging Can Cause Eye Problems Other Than Low Vision Disease
by Ellen Troyer, MT MA CEO & Chief Research Officer, Biosyntrx Just as hair turns gray with age, bladders weaken and memories lapse, our eyes, too, undergo a metamorphosis. Although these changes are all part of normal aging, some set the stage for more serious eye problems. As eyes age, eyelid muscles weaken, and skin becomes [Read More]
Learning to Live with Low Vision: One Man’s Journey Through Rehabilitation
<span data-mce-type=”bookmark” style=”display: inline-block; width: 0px; overflow: hidden; line-height: 0;” class=”mce_SELRES_start”></span><span data-mce-type=”bookmark” style=”display: inline-block; width: 0px; overflow: hidden; line-height: 0;” class=”mce_SELRES_start”></span> Learning to Live With Low Vision: One Man’s Journey Through Rehabilitation Transcript (Free distribution allowed with proper credit given) This is a dramatization of the experiences of Jim, a fictional participant in a low [Read More]
New Anti-Ang2 Drug for Wet AMD Showing Promise
It was reported here in November 2017 that two “anti-Ang2” drugs are being studied as potential combination therapies with established anti-VEGF treatments. RG7716 is being tested in combination with Lucentis (Genentech), and nesvacumab (REGN910) is being tested in combination with Eylea (Regeneron). Genentech has now reported that its Phase 2 BOULEVARD trials with RG7716 have [Read More]